Clinical Trials Directory

Trials / Completed

CompletedNCT02696577

The Effect of Omega 3 on Pregnancy Complicated by Asymmetrical Intrauterine Growth Restriction

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
68 (actual)
Sponsor
Assiut University · Academic / Other
Sex
Female
Age
20 Years – 35 Years
Healthy volunteers
Not accepted

Summary

Intrauterine growth restriction is a common and complex obstetric problem. Intrauterine growth restriction is noted to affect approximately 10-15 % of pregnant women. Intrauterine growth restriction is diagnosed antenatal; however, some of these fetuses, especially if unscreened during pregnancy, may be detected only in the neonatal period. It is very important for obstetricians and perinatologists to identify growth restricted fetuses, because this fetal condition is associated with significant perinatal morbidity and mortality. Omega 3 is composed of polyunsaturated fatty acids with a double bond at the third carbon atom from the end of the carbon chain. The fatty acids have two ends, the carboxylic acid end, which is considered the beginning of the chain, thus "alpha", and the methyl end, which is considered the "tail" of the chain, thus "omega." Omega3 improve fetal wellbeing by two mechanisms: Firstly, maternal and docosahexaenoic acid supplementation during pregnancy and lactation normalizes intrauterine growth restriction induced changes in adipose deposition and visceral PPARγ expression. Secondly, maternal docosahexaenoic acid supplementation increases serum adiponectin, as well as adipose expression of adiponectin and adiponectin receptors. Novel findings suggest that maternal docosahexaenoic acid supplementation normalize adipose dysfunction and promote adiponectin-induced improvements in metabolic function in intrauterine growth restriction

Conditions

Interventions

TypeNameDescription
DRUGLow dose aspirin
DRUGOmega 3

Timeline

Start date
2015-03-01
Primary completion
2016-01-01
Completion
2016-02-01
First posted
2016-03-02
Last updated
2016-03-15

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT02696577. Inclusion in this directory is not an endorsement.